JP2022523524A5 - - Google Patents

Info

Publication number
JP2022523524A5
JP2022523524A5 JP2021549919A JP2021549919A JP2022523524A5 JP 2022523524 A5 JP2022523524 A5 JP 2022523524A5 JP 2021549919 A JP2021549919 A JP 2021549919A JP 2021549919 A JP2021549919 A JP 2021549919A JP 2022523524 A5 JP2022523524 A5 JP 2022523524A5
Authority
JP
Japan
Prior art keywords
seq
fusion protein
amino acid
gpc3
ability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021549919A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523524A (ja
JP7476219B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/054821 external-priority patent/WO2020173897A1/en
Publication of JP2022523524A publication Critical patent/JP2022523524A/ja
Publication of JP2022523524A5 publication Critical patent/JP2022523524A5/ja
Application granted granted Critical
Publication of JP7476219B2 publication Critical patent/JP7476219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021549919A 2019-02-26 2020-02-25 Cd137およびgpc3に特異的な新規融合タンパク質 Active JP7476219B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19000100.8 2019-02-26
EP19000100 2019-02-26
PCT/EP2020/054821 WO2020173897A1 (en) 2019-02-26 2020-02-25 Novel fusion proteins specific for cd137 and gpc3

Publications (3)

Publication Number Publication Date
JP2022523524A JP2022523524A (ja) 2022-04-25
JP2022523524A5 true JP2022523524A5 (cg-RX-API-DMAC7.html) 2022-12-13
JP7476219B2 JP7476219B2 (ja) 2024-04-30

Family

ID=65685094

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549919A Active JP7476219B2 (ja) 2019-02-26 2020-02-25 Cd137およびgpc3に特異的な新規融合タンパク質

Country Status (13)

Country Link
US (1) US12486330B2 (cg-RX-API-DMAC7.html)
EP (1) EP3931209A1 (cg-RX-API-DMAC7.html)
JP (1) JP7476219B2 (cg-RX-API-DMAC7.html)
CN (1) CN113474359B (cg-RX-API-DMAC7.html)
AU (1) AU2020229436B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016829A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124441A1 (cg-RX-API-DMAC7.html)
IL (1) IL284687B2 (cg-RX-API-DMAC7.html)
MA (1) MA55069A (cg-RX-API-DMAC7.html)
MX (1) MX2021010039A (cg-RX-API-DMAC7.html)
SG (1) SG11202106353VA (cg-RX-API-DMAC7.html)
WO (1) WO2020173897A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202104287B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
IL307466A (en) * 2021-04-05 2023-12-01 Cytovia Therapeutics Llc Bispecific antibodies targeting nkp46 and gpc3 and methods of use thereof
AU2022260298A1 (en) * 2021-04-23 2023-11-02 Shanghai Henlius Biotech, Inc. Anti-gpc3 antibodies, multispecific antibodies and methods of use
WO2022242682A1 (en) * 2021-05-21 2022-11-24 Beigene, Ltd. Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
WO2023016564A1 (zh) * 2021-08-12 2023-02-16 上海才致药成生物科技有限公司 靶向GPC3的抗体干扰素α融合蛋白及其用途
WO2023036043A1 (zh) * 2021-09-09 2023-03-16 广东东阳光药业有限公司 抗癌结合分子及其应用
CN113956344A (zh) * 2021-10-14 2022-01-21 江南大学 一种新型治疗肝癌的fgf类似物及其应用
CN113912699A (zh) * 2021-10-14 2022-01-11 江南大学 一种新型治疗乳腺癌的fgf类似物及其应用
CN116640224A (zh) * 2022-02-16 2023-08-25 北京免疫方舟医药科技有限公司 Cd137抗体和cd40l的融合蛋白及其应用
US20250195681A1 (en) * 2022-03-18 2025-06-19 Duality Biologics (Suzhou) Co., Ltd. Anti-gpc3 antibody drug conjugate and use thereof
WO2023180523A1 (en) 2022-03-24 2023-09-28 Pieris Pharmaceuticals Gmbh Process for purifying fusion proteins
CN122255279A (zh) * 2022-11-21 2026-06-23 广州百济神州生物制药有限公司 抗cd137抗体和使用方法
CN119613552B (zh) * 2024-07-23 2025-11-28 艾可泰科(浙江)控股有限公司 一组抗人gpc3纳米抗体突变体及嵌合抗原受体和应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンaの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
JP3839667B2 (ja) 1998-06-08 2006-11-01 エフ.ホフマン−ラ ロシュ アーゲー 慢性C型肝炎の処置のためのPeg−INF−アルファ及びリバビリンの使用
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7892827B2 (en) 2004-11-26 2011-02-22 Pieris Ag Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4)
AU2006294644A1 (en) 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
EP1996613B1 (en) 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
DE602007009995D1 (de) 2006-08-01 2010-12-02 Pieris Ag Muteine von tearlipocalin und verfahren zu deren gewinnung
KR20150126724A (ko) * 2007-09-28 2015-11-12 추가이 세이야쿠 가부시키가이샤 혈장 중 반응속도가 개선된 항-글리피칸-3 항체
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
WO2013174783A1 (en) * 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
JP2015536933A (ja) * 2012-10-23 2015-12-24 オンコメッド ファーマシューティカルズ インコーポレイテッド Wnt経路結合剤を用いて神経内分泌腫瘍を処置する方法
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
RU2727165C2 (ru) 2015-05-04 2020-07-21 ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ Слитый полипептид с противораковой активностью
PH12017501583B1 (en) * 2015-05-04 2023-01-20 Pieris Pharmaceuticals Gmbh Novel proteins specific for cd137
DK3298030T5 (en) * 2015-05-18 2024-10-07 Pieris Pharmaceuticals Gmbh Anti-cancerfusionspolypeptid
EP3298029A1 (en) * 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
WO2018087108A1 (en) * 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
US20200040084A1 (en) * 2017-01-06 2020-02-06 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
WO2018228442A1 (en) * 2017-06-14 2018-12-20 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof

Similar Documents

Publication Publication Date Title
JP7827324B2 (ja) インターロイキン-2バリアントおよびその使用方法
JP7529734B2 (ja) IL15/IL15Rαヘテロ二量体FC-融合タンパク質
JP7850417B2 (ja) 新規インターロイキン-2バリアントおよびその二官能性融合分子
EP3180361B1 (en) Recombinant antibody molecule and its use for target cell restricted t cell activation
JP2021533203A5 (cg-RX-API-DMAC7.html)
JP2022177090A (ja) 腫瘍壊死因子 (tnf) スーパーファミリー受容体結合分子およびその使用
JP7536294B2 (ja) 抗体のFc領域改変体
DK2536764T3 (en) ANTI-CD28 HUMANIZED ANTIBODIES
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
JP2021506291A (ja) 改変されたil−2 fc融合タンパク質
JP2019502694A (ja) 二特異性抗体基幹
JP2018510623A (ja) Nkg2d及び腫瘍関連抗原に対する二価抗体
JP2018519803A5 (cg-RX-API-DMAC7.html)
KR20160034404A (ko) Fc-함유 폴리펩타이드의 안정화
CN111699201A (zh) 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法
JP2025160405A (ja) 特異的結合分子
EP1737963A1 (fr) Utilisation du gene codant la chaine beta de la proteine c4bp dans la production de proteines dimeriques recombinantes
JP2023542049A (ja) インターロイキン-2ムテイン及びその使用
CN112969477B (zh) 改善肽的血液动力学的方法
CN115551538A (zh) 干扰IL-1β受体信号转导的药剂
RU2021121116A (ru) Новые слитые белки, специфические в отношении cd137 и gpc3
CN115702169A (zh) 包含促红细胞生成素多肽的融合蛋白
WO2021143733A1 (zh) 一种融合蛋白及其制法和用途
JP7857307B2 (ja) 腫瘍壊死因子-アルファおよびトランスフォーミング増殖因子-ベータの二機能性アンタゴニストならびにその使用
RU2815388C2 (ru) Многофункциональные слитые белки и их применения